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Introduction
Retinal vein occlusion is a common cause of vision loss worldwide1 and is the second
most common retinal vascular disease after diabetic retinopathy.2 The Beaver Dam
Eye Study found that the prevalence of central retinal vein occlusion (CRVO) was
0.1% and the 5-year incidence was 0.2%, while the 15-year cumulative incidence of
CRVO is 0.5%.3,4 Most recently, a pooled analysis of data from .68,000 individuals
found that 2.5 million adults are affected by CRVO.5 Pharmacologic therapies such as
intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and intravitreal
steroids are shown to be of benefit for eyes with macular edema secondary to CRVO.6
Due to the side effects associated with steroid use, including increased intraocular
pressure and cataract, anti-VEGF agents have emerged as first-line therapy for most
eyes with retinal vein occlusions.
Two anti-VEGF agents are currently approved by the US Food and Drug
Administration for the treatment of macular edema due to CRVO: ranibizumab and
aflibercept. Bevacizumab is additionally used for this indication on an off-label basis.
Aflibercept is a fusion protein of key domains from human VEGF receptors 1 and 2
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Objectives: To report on the efficacy and safety of intravitreal aflibercept in patients with
macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis
of COPERNICUS and GALILEO.
Patients and methods: Patients were randomized to receive intravitreal aflibercept 2 mg
every 4 weeks or sham injections until week 24. From week 24 to week 52, all intravitreal
aflibercept-treated patients in both studies and sham-treated patients in COPERNICUS were
eligible to receive intravitreal aflibercept based on prespecified criteria. In GALILEO, shamtreated patients continued to receive sham treatment through week 52.
Results: At week 24, mean gain in best-corrected visual acuity and mean reduction in central
retinal thickness were greater for intravitreal aflibercept-treated patients compared with sham,
consistent with individual trial results. At week 52, after 6 months of intravitreal aflibercept
as-needed treatment in COPERNICUS, patients originally randomized to sham group experienced visual and anatomic improvements but did not improve to the extent of those initially
treated with intravitreal aflibercept, while the sham group in GALILEO did not improve over
week 24 mean best-corrected visual acuity scores. Ocular serious adverse events occurred
in ,10% of patients.
Conclusion: This analysis of integrated data from COPERNICUS and GALILEO confirmed
that intravitreal aflibercept is an effective treatment for macular edema following CRVO.
Keywords: macular edema, central retinal vein occlusion, anti-vascular endothelial growth
factor, aflibercept, COPERNICUS, GALILEO
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with the constant region (Fc) of human immunoglobulin G
that binds to multiple VEGF-A isoforms with a high
affinity.7,8 Intravitreal aflibercept was approved for the
treatment of macular edema due to CRVO after its efficacy
and safety were demonstrated in the two Phase III studies,
COPERNICUS and GALILEO.9–14
Results of the integrated analyses from COPERNICUS
and GALILEO have not been published. Integrating data
from both studies increases the number of patients included
in the treated population, thus increasing the generalizability
of the results to the global population and minimizing the
risk of any outlier effect that might be seen in the individual
studies. Integrating the data also strengthens the ability to
detect any safety signals and characterizes the safety profile
of intravitreal aflibercept. Here, we report on the efficacy and
safety of intravitreal aflibercept at 52 weeks in patients with
macular edema secondary to CRVO in an integrated analysis
of data from the COPERNICUS and GALILEO studies.
Sham-treated patients in the COPERNICUS study were
eligible to receive intravitreal aflibercept starting at week 24,
whereas patients in GALILEO continued sham treatment
through week 52. As treatment schedules and the duration
of the two studies differed beyond week 52, integrated data
are shown here only through the week 52 visits.

on ClinicalTrials.gov as NCT00943072 and NCT01012973,
respectively. Institutional Review Board/Ethics Committee
approval was obtained at each site before the start of the studies
(Supplementary materials). All patients signed a written
consent form before initiation of study-specific procedures.

Patients and methods
Design

Randomization and treatments

COPERNICUS and GALILEO were parallel randomized,
double-masked Phase III studies comparing intravitreal
aflibercept with sham for the treatment of macular edema
secondary to CRVO. The details of these studies have been
published previously;9–14 key aspects of study design and
conduct are described here. COPERNICUS was conducted
at 61 sites in the United States, Canada, Colombia, India,
and Israel and GALILEO at 63 sites in Asia and Europe. The
duration of COPERNICUS was 100 weeks and GALILEO
was 76 weeks. The studies were conducted in compliance
with ethical guidelines from the Declaration of Helsinki and
International Conference on Harmonisation and are registered

Patients
Patients with center-involved macular edema due to CRVO
for #9 months were included if they were treatment naïve,
aged $18 years, and had a mean central retinal thickness
(CRT) $250 µm on optical coherence tomography and
a best-corrected visual acuity (BCVA) of 73–24 Early
Treatment Diabetic Retinopathy Study (ETDRS) letters in
the study eye. Only one eye per patient was included.
Exclusion criteria comprised the following: pregnancy
or lactation; uncontrolled glaucoma (intraocular pressure $25 mmHg); cataract, vitreoretinal, or filtration surgery;
bilateral manifestation of retinal vein occlusion; iris neovascularization; any ocular disorder in the study eye that, in the
opinion of the investigator, may have confounded the interpretation of the study results; or previous treatment with any
anti-VEGF agents, systemic anti-angiogenic medications,
or intraocular corticosteroids. Retinal ischemia and afferent
pupillary defect were not causes for exclusion.

Patients were randomized in a 3:2 ratio to receive intravitreal
aflibercept 2 mg every 4 weeks or sham injections until
week 24. From week 24 to week 52, all intravitreal
aflibercept-treated patients in both studies and sham-treated
patients in COPERNICUS were eligible to receive intravitreal aflibercept based on prespecified retreatment criteria.
Sham-treated patients in GALILEO were eligible to receive
intravitreal aflibercept after week 52. Treatment groups are
shown in Table 1.
The prespecified retreatment criteria included increase
of .50 µm from lowest previous measurement, new/
persistent cystic retinal changes or subretinal fluid or
persistent diffuse edema of $250 µm in the central subfield,

Table 1 Treatment groups
Treatment
groups

COPERNICUS
Baseline to week 20

Week 24 to week 52

Baseline to week 20

Week 24 to week 52

Sham

Sham injection every
4 weeks
Intravitreal aflibercept
2.0 mg every 4 weeks

Intravitreal aflibercept
2.0 mg PRN
Intravitreal aflibercept
2.0 mg PRN

Sham injection every
4 weeks
Intravitreal aflibercept
2.0 mg every 4 weeks

Sham injection every
4 weeks
Intravitreal aflibercept
2.0 mg PRN

Intravitreal
aflibercept

GALILEO

Abbreviation: PRN, pro re nata (as needed).
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loss of $5 ETDRS letters from best previous measurement
with any increase in CRT, and increase of $5 ETDRS letters
between current and most recent visit in the absence of retinal
edema in the central subfield. Patients who did not meet
any of the retreatment criteria were given sham injections
to maintain masking. In case of neovascular complications
(eg, neovascularization of the anterior segment, at the optic
disk, or elsewhere in the fundus), patients were eligible for
treatment with panretinal photocoagulation.

continuous variables by sample statistics (ie, mean, standard
deviation). Patients included in the evaluations are those from
the full analysis set, which includes all randomized subjects
who received any study medication and had at least one
baseline and one post-baseline assessment. The full analysis
set was analyzed as randomized. For missing efficacy data
after start of treatment, the last observation carried forward
(LOCF) approach was applied. Safety analysis included all
patients who received any study treatment.

Outcomes

Results

The primary end point was the proportion of eyes that
gained $15 letters in BCVA at week 24. Herein, results are
presented for the integrated COPERNICUS and GALILEO
studies. Results from baseline to week 24 are presented for
two groups of patients: the intravitreal aflibercept group
(n=217) and the sham group (n=141). Results from week 24
to week 52 are presented for three groups of patients: the
intravitreal aflibercept group (n=217), the sham → intravitreal aflibercept group (ie, patients in COPERNICUS
originally randomized to sham injections who crossed over
to active treatment after week 24; n=73), and the sham group
(ie, patients in GALILEO originally randomized to sham
injections who had not crossed over to active treatment by
week 52; n=68).

When data from the two studies were integrated, baseline
demographic and disease characteristics were similar across
the two treatment groups (Table 2). Mean age at baseline was
62.9 years in the intravitreal aflibercept group and 65.7 years
in the sham group. Mean baseline BCVA was 52.0 letters in
the intravitreal aflibercept group and 49.9 letters in the sham
group. The majority of patients in both treatment groups
had perfused retinas (classified as ,10 disk areas of retinal
capillary non-perfusion on fluorescein angiography) at
baseline (76.5% of patients in the intravitreal aflibercept
group and 73.8% in the sham group). There were fewer
patients with perfused retinas at baseline in COPERNICUS
than GALILEO (67.9% versus 83.6%).
From baseline to week 24, the mean (standard deviation)
number of injections received in the intravitreal aflibercept
group was 5.8 (0.8). Among patients who completed at least
through week 24, the mean (standard deviation) number of
active injections received from week 24 to week 52 was
2.6 (1.7) in the intravitreal aflibercept group, 3.9 (2.0) in

Statistics
All safety and efficacy variables were analyzed descriptively
with appropriate statistical methods: categorical variables
by frequency tables (absolute and relative frequencies) and

Table 2 Baseline demographic and disease characteristics (full analysis set)

Mean (SD) age, years
Sex, female, n (%)
Mean (SD) BCVA, ETDRS letters
Mean (SD) CRT, µm
Mean (SD) time since CRVO diagnosis, months
Perfusion status, n (%)
Perfused
Non-perfused
Indeterminate
Retinal fluid, n (%)
Absent
Present
Undetermined

COPERNICUS
(n=187)

GALILEO
(n=171)

Integrated
Intravitreal aflibercept
group (n=217)

Sham group
(n=141)

66.3 (13.9)
80 (43.0)
50 (14.1)
665.8 (239.8)
2.4 (2.8)

61.5 (12.9)
76 (44.4)
52.2 (15.7)
665.5 (231.0)
n/aa

62.9 (13.3)
127 (58.5)
52.0 (14.9)
672.0 (235.7)
2.7 (3.0)

65.7 (13.9)
66 (46.8)
49.9 (14.9)
655.7 (235.1)
2.4 (2.5)

127 (67.9)
29 (15.5)
31 (16.6)

143 (83.6)
14 (8.2)
14 (8.2)

166 (76.5)
24 (11.1)
27 (12.4)

104 (73.8)
19 (13.5)
18 (12.8)

3 (1.6)
182 (97.9)
1 (0.5)

2 (1.2)
168 (98.2)
1 (0.6)

4 (1.8)
211 (97.2)
2 (1.0)

1 (0.7)
139 (99.3)
0

Note: aFor GALILEO, time since diagnosis reported in days: mean (SD) = 81.8 (85.4).
Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; CRVO, central retinal vein occlusion; ETDRS, Early Treatment Diabetic Retinopathy Study;
n/a, not available; SD, standard deviation.
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Figure 1 Mean change in BCVA for (A) COPERNICUS and GALILEO and (B) integrated data set from baseline to week 24 (LOCF).
Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; LOCF, last observation carried forward.

the sham → intravitreal aflibercept group, and 0 (0) in the
sham group.
At week 24, the proportion of patients who
gained $15 letters from baseline was 60.4% in the intravitreal aflibercept group and 17.0% in the sham group. At
week 52, the proportion of patients who gained $15 letters
from baseline was 58.5% in the intravitreal aflibercept
group, 30.1% in the sham → intravitreal aflibercept group
(COPERNICUS), and 32.4% in the sham group (GALILEO).
Between week 24 and week 52, the proportion of patients
who gained $15 letters from baseline increased by
17.8 percentage points in the sham → intravitreal aflibercept
group and by 10.3 percentage points in the sham group.
At week 24, the mean change in BCVA from baseline was +17.7 letters in the intravitreal aflibercept group
and -0.5 letters in the sham group (Figure 1). At week 52,
the mean change in BCVA from baseline was +16.5 letters in
the intravitreal aflibercept group, +3.8 letters in the sham →
intravitreal aflibercept group, and +3.8 letters in the sham
group (Figure 2). Between week 24 and week 52, the mean
change from baseline in BCVA increased by 7.8 letters in
the sham → intravitreal aflibercept group, and by 0.5 letters
in the sham group.
At week 24, the mean change in CRT from baseline was -453.1 µm in the intravitreal aflibercept group
and -157.2 µm in the sham group (Figure 3). At week 52,
the mean change in CRT from baseline was -418.0 µm in
the intravitreal aflibercept group, -381.8 µm in the sham →
intravitreal aflibercept group, and -219.3 µm in the sham
group (Figure 4).
At week 52, ocular serious adverse events occurred
in 16 (7.3%), 12 (16.2%), and six (8.8%) patients in the
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intravitreal aflibercept group, the sham → intravitreal
aflibercept group, and the sham group, respectively
(Table 3). Two Antiplatelet Trialists Collaboration-defined
arterial thromboembolic events (APTC-ATEs) occurred
overall. One patient in the intravitreal aflibercept group
experienced a non-fatal myocardial infarction and one
patient in the sham → intravitreal aflibercept group experienced vascular death. There were no APTC-ATEs in the
sham group (Table 4).

Discussion
The aim of this article is to report the efficacy and safety
of intravitreal aflibercept in patients with macular edema
due to CRVO in an integrated analysis of data from the
COPERNICUS and GALILEO studies. The integrated data
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Figure 2 Mean change in BCVA from baseline to week 24–week 52 (LOCF).
Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment
Diabetic Retinopathy Study; LOCF, last observation carried forward.

Clinical Ophthalmology 2017:11

Dovepress

Integrated results from COPERNICUS and GALILEO

$








:HHN


%






Clinical Ophthalmology downloaded from https://www.dovepress.com/ by 147.140.233.17 on 21-Sep-2017
For personal use only.

±
±
±

±
±

±

&23(51,&86LQWUDYLWUHDODIOLEHUFHSW Q 
&23(51,&86VKDP Q 
*$/,/(2LQWUDYLWUHDODIOLEHUFHSW Q 
*$/,/(2VKDP Q 





:HHN








±

±
±

P

P

±





±

±
±
±

±

±
,QWUDYLWUHDODIOLEHUFHSW Q 
6KDP Q 

Figure 3 Mean change in CRT for (A) COPERNICUS and GALILEO and (B) integrated data set from baseline to week 24 (LOCF).
Abbreviations: CRT, central retinal thickness; LOCF, last observation carried forward.

of the COPERNICUS and GALILEO studies confirm the
findings of the individual studies.
Both the COPERNICUS and GALILEO studies documented the beneficial treatment effect of intravitreal aflibercept compared with sham injections; however, there were
differences between the studies that should be considered.
The natural history (sham-treated) groups demonstrate that
the patients enrolled in the two studies were slightly different
in some aspects, likely due in part to the different countries
and geographic regions where they were conducted. Specifically, visual gains among patients originally randomized to
sham treatment were generally lower in COPERNICUS than
those in GALILEO, both before and after initiation of treatment with intravitreal aflibercept at week 24. This finding



:HHN







P

±
±

±

±
±
±
±
±

±
±

&23(51,&86LQWUDYLWUHDODIOLEHUFHSW Q 
&23(51,&86VKDPĺLQWUDYLWUHDODIOLEHUFHSW Q 
*$/,/(2LQWUDYLWUHDODIOLEHUFHSW Q 
*$/,/(2VKDP Q 
,QWHJUDWHGLQWUDYLWUHDODIOLEHUFHSW Q 
Figure 4 Mean change in CRT from baseline to week 24–week 52 (LOCF).
Abbreviations: CRT, central retinal thickness; LOCF, last observation carried
forward.
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may be due to the larger number of patients with non-perfused
retinas at baseline in COPERNICUS compared with
GALILEO10,13 or to some other unidentified factor(s).
The data from the sham → intravitreal aflibercept group
in COPERNICUS support that a 6-month delay in initiating
treatment with intravitreal aflibercept can result in diminished
visual and morphologic gains, and after 12 months without
treatment, as observed in GALILEO, sham treatment did
not show additional visual improvements beyond the small
gains seen at week 24. At week 24, after receiving 6-monthly
injections of intravitreal aflibercept, patients in the intravitreal
aflibercept group experienced greater visual gains compared
with patients who received sham treatment (+17.7 letters
versus -0.5 letters for the sham group). From week 24 to
week 52, visual acuity gains were maintained in the intravitreal aflibercept group. The visual outcomes at week 52
in the sham group of COPERNICUS that crossed over to
receive intravitreal aflibercept at week 24 did not reach the
level of those attained by patients who received intervention
with intravitreal aflibercept at the start of the study, despite
a marked improvement in anatomy. Furthermore, patients
in the GALILEO study who did not cross over to treatment
with intravitreal aflibercept until week 52 also did not show
any meaningful visual gains. These data suggest that a delay
in treatment initiation with intravitreal aflibercept may result
in less optimal visual outcomes.
Integrated morphologic results at week 24 followed
the same pattern as the visual results. At week 24, the
improvements in CRT from baseline were greater in the
intravitreal aflibercept group than in the sham group (-453.1
versus -157.2 µm), and these improvements were maintained
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Table 3 Ocular SAEs from baseline to week 52 by MedDRA Preferred Term (safety analysis set)
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Patients with $1 SAE in
the study eye, n (%)
Cataract
Corneal abrasion
Cystoid macular edema
Endophthalmitis
Glaucoma
Iris neovascularization
Macular fibrosis
Macular ischemia
Macular edema
Retinal artery occlusion
Retinal hemorrhage
Retinal tear
Retinal vein occlusion
Visual acuity reduced
Vitreous detachment
Vitreous hemorrhage

Intravitreal aflibercept
group (n=218)

Sham → intravitreal
aflibercept group (n=74)

Sham group
(n=68)

All patients
(n=360)

16 (7.3)

12 (16.2)

6 (8.8)

34 (9.4)

1 (0.5)
1 (0.5)
1 (0.5)
1 (0.5)
0
1 (0.5)
1 (0.5)
1 (0.5)
4 (1.8)
1 (0.5)
0
0
2 (0.9)
1 (0.5)
1 (0.5)
2 (0.9)

1 (1.4)
0
0
0
3 (4.1)
2 (2.7)
0
0
0
0
2 (2.7)
2 (2.7)
1 (1.4)
1 (1.4)
0
5 (6.8)

0
0
0
0
2 (2.9)
0
0
0
2 (2.9)
0
0
0
0
1 (1.5)
0
1 (1.5)

2 (0.6)
1 (0.3)
1 (0.3)
1 (0.3)
5 (1.4)
3 (0.8)
1 (0.3)
1 (0.3)
6 (1.7)
1 (0.3)
2 (0.6)
2 (0.6)
3 (0.8)
3 (0.8)
1 (0.3)
8 (7.8)

Abbreviation: SAE, serious adverse event.

in the intravitreal aflibercept group through week 52.
Although CRT improvements were substantial in the sham →
intravitreal aflibercept group, anatomic improvements were
not mirrored by similar improvements in visual acuity, confirming the importance of early intervention in eyes with
macular edema due to CRVO. It should be noted that LOCF
data generally leave a gap between patients treated from baseline and patients receiving rescue later on due to dropouts,
resulting in an underestimation of the effect of crossover.
The benefits of early treatment have been seen in other
studies of patients with CRVO. Analyses of eyes treated with
dexamethasone intravitreal implant15 and with ranibizumab16
in the Phase III trials of these drugs have demonstrated that
although the macula can be dried effectively even after a
delay in treatment, visual improvements do not catch up to
those achieved in earlier-treated eyes.
The results of this integrated analysis of COPERNICUS
and GALILEO are consistent with the safety profile of

intravitreal aflibercept. The ocular serious adverse events
observed in this study largely comprised adverse events
attributable to the underlying disease.

Conclusion
Based on the integrated data from the COPERNICUS and
GALILEO studies, intravitreal aflibercept is a well-tolerated
and effective treatment for macular edema secondary to
CRVO. The integrated data show that macular edema
secondary to CRVO can be managed successfully with initial
monthly intravitreal aflibercept injections, consistent with
results shown in the respective trials.10,12 Delay in treatment
initiation with intravitreal aflibercept in the COPERNICUS
study resulted in limited gains in visual acuity by week 52.
The integrated results of these studies reinforce the robustness of the treatment effect of intravitreal aflibercept in
retinal vein occlusions to maximize visual and morphologic
benefits.

Table 4 APTC-ATEs from baseline to week 52 (safety analysis set)

Patients with any APTC-ATE, n (%)
Non-fatal myocardial infarction
Non-fatal stroke
Vascular death

Intravitreal aflibercept
group (n=218)

Sham → intravitreal
aflibercept group (n=74)

Sham group
(n=68)

All patients
(n=360)

1 (0.5)
1 (0.5)
0
0

1 (1.4)
0
0
1 (1.4)

0
0
0
0

2 (0.6)
1 (0.3)
0
1 (0.3)

Abbreviation: APTC-ATEs, Antiplatelet Trialists Collaboration-defined arterial thromboembolic events.
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